4-Quinazolinyloxy-diaryl ureas as novel BRAFV600E inhibitors (original) (raw)
Challenges and Opportunities in the Crusade of BRAF Inhibitors: From 2002 to 2022
Mariusz Jaremko
ACS Omega, 2023
View PDFchevron_right
Small molecules against B-RAF (BRAF) Val600Glu (V600E) single mutation
Mihai Muresan
International Journal of Nanomedicine, 2015
View PDFchevron_right
Demonstration of a Genetic Therapeutic Index for Tumors Expressing Oncogenic BRAF by the Kinase Inhibitor SB-590885
hieu do
Cancer Research, 2006
View PDFchevron_right
BRAF inhibitors: From the laboratory to clinical trials
Alfred Lam
Critical Reviews in Oncology/Hematology, 2013
View PDFchevron_right
CEP-32496: A Novel Orally Active BRAFV600E Inhibitor with Selective Cellular and In Vivo Antitumor Activity
Merryl Cramer
Molecular Cancer Therapeutics, 2012
View PDFchevron_right
Advances in Pharmacology and Clinical Trials Study the Efficacy of Sorafenib, Vemurafenib and Dabrafenib on BRAF Wild and Mutated Genes Using Computational Approach
Inas sadawi
View PDFchevron_right
LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors
Emma Labrot
Clinical Cancer Research, 2020
View PDFchevron_right
Searching new structural scaffolds for BRAF inhibitors. An integrative study using theoretical and experimental techniques
Ludmila Campos
Bioorganic Chemistry, 2019
View PDFchevron_right
Functional characterization of a PROTAC directed against BRAF mutant V600E
David Uehling
Nature Chemical Biology, 2020
View PDFchevron_right
BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis
Jaleel Shujath
Cancer Research, 2004
View PDFchevron_right
A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation
N. Kraut
Molecular cancer therapeutics, 2016
View PDFchevron_right
A cell-based screening to detect inhibitors of BRAF signaling pathway
Mihoko Mori
Journal of Antibiotics, 2009
View PDFchevron_right
Identification of 1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea Hydrochloride (CEP-32496), a Highly Potent and Orally Efficacious Inhibitor of V-RAF Murine Sarcoma Viral Oncogene Homologue B1 (BRAF) V600E
Merryl Cramer
Journal of Medicinal Chemistry, 2012
View PDFchevron_right
Highly potent and selective 3-N-methylquinazoline-4(3H)-one based inhibitors of B-RafV600E kinase
David Moreno Moreno
Bioorganic & Medicinal Chemistry Letters, 2014
View PDFchevron_right
Identification of Inhibitors of the Kinase Activity of Oncogenic V600EBRAF in an Enzyme Cascade High-Throughput Screen
Steven Whittaker
Journal of Biomolecular Screening, 2005
View PDFchevron_right
Synthesis, biological evaluation of novel 4,5-dihydro-2H-pyrazole 2-hydroxyphenyl derivatives as BRAF inhibitors
Dong Li
Bioorganic & Medicinal Chemistry, 2012
View PDFchevron_right
The multifaceted anti-cancer effects of BRAF-inhibitors
Laura Croce
Oncotarget
View PDFchevron_right
Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach
Timothy Lowinger
Bioorganic & Medicinal Chemistry Letters, 2001
View PDFchevron_right
Design, synthesis, anticancer evaluation and molecular docking of new V600EBRAF inhibitors derived from pyridopyrazinone
Prof. Mandava venkata Basaveswara Rao
European Journal of Chemistry, 2016
View PDFchevron_right
Small molecule inhibitors of BRAF in clinical trials
Ion Niculescu-duvaz
Bioorganic & Medicinal Chemistry Letters, 2012
View PDFchevron_right
Omega-carboxypyridyl substituted ureas as Raf kinase inhibitors
Timothy Lowinger
Bioorganic & Medicinal Chemistry Letters, 2004
View PDFchevron_right
Computer-aided design and synthesis of 3-carbonyl-5-phenyl-1H-pyrazole as highly selective and potent BRAFV600E and CRAF inhibitor
waqar aman
Journal of Enzyme Inhibition and Medicinal Chemistry, 2019
View PDFchevron_right
Novel Potent BRAF Inhibitors: Toward 1 nM Compounds through Optimization of the Central Phenyl Ring
Adrian Gill
Journal of Medicinal Chemistry, 2009
View PDFchevron_right
The identification of potent, selective and CNS penetrant furan-based inhibitors of B-Raf kinase
Elaine Irving
Bioorganic & Medicinal Chemistry Letters, 2008
View PDFchevron_right
Discovery of potent, orally active compounds of tyrosine kinase and Serine/threonine-protein kinase inhibitor with anti-tumor activity in preclinical assays
Yunqing Qiu
African Journal of Traditional, Complementary and Alternative Medicines, 2012
View PDFchevron_right
Design and synthesis of 5,6-fused heterocyclic amides as Raf kinase inhibitors
Sylvia Ma
Bioorganic & Medicinal Chemistry Letters, 2011
View PDFchevron_right
Mechanism of Dimer Selectivity and Binding Cooperativity of BRAF inhibitors
evangelia matenoglou
bioRxiv (Cold Spring Harbor Laboratory), 2023
View PDFchevron_right